Trastuzumab (anti-HER2)

Catalog No.A2007        Batch: A200706

Print

Technical Data

CAS No. 180288-69-1
Formulation 1×PBS, pH6.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99.84%
Protein concentration 3.27 mg/ml
Endotoxin Level <1 EU/mg

Biological Activity

Description Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Targets
HER2 [1]
In vitro

Loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.[1]
In vivo

Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumor volume between the group treated with AZD5438 combined with trastuzumab and those treated with AZD5438 or trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.[2]

Protocol (Only for Reference)

Cell Assay:

  • OE19 cells transduced with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of trastuzumab for 6 days.
Animal Study:

  • AnimalModels:Female BALB/c nude mice of ERBB2-positive alpha-fetoprotein producing gastric carcinoma patient-derived xenograft models
    Dosages:10 mg/kg
    Administration:i.p.[2]

     

Customer Product Validation

Selleck's Trastuzumab (anti-HER2) has been cited by 32 publications

Intracellular cartilage oligomeric matrix protein augments breast cancer resistance to chemotherapy [ Cell Death Dis, 2024, 15(7):480] PubMed: 38965233
Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo [ Eur J Med Chem, 2024, 264:116014] PubMed: 38061230
Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer [ Biochim Biophys Acta Mol Basis Dis, 2024, 1870(8):167458] PubMed: 39128642
Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression [ Int J Biol Sci, 2023, 19(2):377-392] PubMed: 36632463
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer [ Cell Death Dis, 2023, 14(8):532] PubMed: 37596261
Detecting Disruption of HER2 Membrane Protein Organization in Cell Membranes with Nanoscale Precision [ ACS Sens, 2023, 10.1021/acssensors.3c01437] PubMed: 37955934
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity [ Cell Rep, 2023, 42(7):112797] PubMed: 37436890
Engineering choroid plexus-on-a-chip with oscillatory flow for modeling brain metastasis [ Mater Today Bio, 2023, 22:100773] PubMed: 37664794
Engineering choroid plexus-on-a-chip with oscillatory flow for modeling brain metastasis [ Mater Today Bio, 2023, 22:100773] PubMed: 37664794
Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells [ Int J Mol Sci, 2023, 24(7)6791] PubMed: 37047765

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.